NeuroBo Pharmaceuticals, Inc. (NRBO)

NASDAQ: NRBO · IEX Real-Time Price · USD
3.810
-0.110 (-2.81%)
At close: Jun 14, 2024, 3:16 PM
3.980
+0.170 (4.46%)
After-hours: Jun 14, 2024, 5:47 PM EDT
-2.81%
Market Cap 18.69M
Revenue (ttm) n/a
Net Income (ttm) -16.58M
Shares Out 4.91M
EPS (ttm) -3.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,469
Open 3.940
Previous Close 3.920
Day's Range 3.800 - 3.950
52-Week Range 2.888 - 6.750
Beta -0.34
Analysts Strong Buy
Price Target 10.00 (+162.47%)
Earnings Date Aug 7, 2024

About NRBO

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functi... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Hyung-Heon Kim
Employees 8
Stock Exchange NASDAQ
Ticker Symbol NRBO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for NRBO stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target
$10.0
(162.47% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

Data Will be Presented in Two Posters at the EASL Congress 2024 CAMBRIDGE, Mass. , May 22, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company foc...

23 days ago - PRNewsWire

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third Quarter of 2024 Anticipate First Patient t...

5 weeks ago - PRNewsWire

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

CAMBRIDGE, Mass. , April 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today ...

6 weeks ago - PRNewsWire

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the Third Quarter of 2024 First Patient Dosed in the Multiple Ascendi...

2 months ago - PRNewsWire

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Full Data Readout Expected in the Second Half of 2024 CAMBRIDGE, Mass. , April 1, 2024  /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on ...

2 months ago - PRNewsWire

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Received First Site Institutional Review Board (IRB) Approval  to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose First Patient in Second Quarter of 2024...

2 months ago - PRNewsWire

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification Full Data Readout Expected in the Second Half of 2024 CA...

3 months ago - PRNewsWire

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

CAMBRIDGE, Mass., March 4, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases of cardiometabolic...

3 months ago - PRNewsWire

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

First Patient Expected to be Randomized in the Second Quarter of 2024 CAMBRIDGE, Mass. , Feb. 29, 2024 /PRNewswire/ --  NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology com...

3 months ago - PRNewsWire

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

CAMBRIDGE, Mass. , Feb. 12, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced ...

4 months ago - PRNewsWire

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Preclinical Studies Show DA-1726 Elicits Superior Weight Loss Compared to Semaglutide (Wegovy™) and Similar Weight Loss Compared to Tirzepatide (Mounjaro™), While Consuming More Food Initiation of Pha...

4 months ago - PRNewsWire

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Full Data Readout Expected in the Second Half of 2024 CAMBRIDGE, Mass. , Jan. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on t...

5 months ago - PRNewsWire

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that on ...

5 months ago - PRNewsWire

NeuroBo to Participate in Industry and Investor Conferences in January

CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced p...

5 months ago - PRNewsWire

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

CAMBRIDGE, Mass. , Dec. 28, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced ...

6 months ago - PRNewsWire

NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Commencement of Trading on Split-Adjusted Basis on December 21, 2023 BOSTON , Dec. 19, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused...

6 months ago - PRNewsWire

NeuroBo to Participate in Investor Conferences in December

BOSTON , Dec. 1, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc.  (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced t...

7 months ago - PRNewsWire

NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

DA-1726 Phase 1 IND Filing Expected by Year End 2023 Board Strengthened with Recent Appointment of Industry Veteran, James P. Tursi, M.D.

7 months ago - PRNewsWire

NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.

BOSTON , Nov. 6, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appoint...

7 months ago - PRNewsWire

NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference

BOSTON , Oct. 17, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that Hyung...

8 months ago - PRNewsWire

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

Two-Part Design Provides Optionality for Interim Analysis in First Half of 2024 Full Data Readout Expected in the Second Half of 2024 BOSTON , Sept. 15, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, I...

9 months ago - PRNewsWire

NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT

BOSTON , Aug. 14, 2023  /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appoi...

10 months ago - PRNewsWire

NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Dosing of First Patient in Phase 2a Clinical Trial of DA-1241 Expected September 2023 Cash and Cash Equivalents of $28.7 Million, Expected to Fund the Company into 2024, Through Multiple Clinical Mile...

11 months ago - PRNewsWire

NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

BOSTON , Aug. 3, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has...

11 months ago - PRNewsWire

NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01

BOSTON , Aug. 2, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has...

11 months ago - PRNewsWire